PLATINIUM, released simultaneously in both Europe and Japan by LivaNova (formerly Sorin Group), will protect patients from avoidable replacement surgeries and the inherent risk of complications.

San Francisco, CA - When a heart-failure patient has a defibrillator-equipped cardiac resynchronization therapy (CRT-D) device, antitachycardia pacing (ATP) is preferable to a shock for the treatment ...

Please provide your email address to receive an email when new articles are posted on . Among the features of the new European Society of Cardiology guideline on pacing and cardiac resynchronization ...

Implanted devices that treat cardiac dysfunction in heart failure patients are as successful in "real world" use as they are in controlled clinical trial settings, according to a large new study ...

Please provide your email address to receive an email when new articles are posted on . Medtronic recalled ICDs and CRT-Ds with a glassed feedthrough made after Oct. 13, 2017 due to risk for low- or ...

The U.S. FDA has given its nod to Abbott Laboratories' next-generation Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The ...

The major trials that established cardiac resynchronization therapy (CRT) as a treatment for heart failure (HF) with reduced ejection fraction (HFrEF) tended not to include patients who already had ...